Equities

Bioservo Technologies AB

10B:MUN

Bioservo Technologies AB

Actions
  • Price (EUR)0.05
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-25.37%
  • Beta0.6288
Data delayed at least 15 minutes, as of Jun 28 2024 07:22 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioservo Technologies AB is a Sweden-based company within wearable technologies based on bionic soft robotics. It is engaged in developing, producing and selling muscle strengthening equipment based on the patented SEM Technology (Soft Extra Muscle Technology). The technology implies so called intention detection logic that activates the support if the wearer initiates movement with a natural and intuitive movement. This is achieved by sensors that detect the user’s action and strengthens this action by activating the motors. Its main product is a SEM Glove. The products are designed for people that have an impaired grip strength caused by injured nerves, weakening in the muscles or pain in the muscles/muscular attachments. The product is applicable in the healthcare and industry sectors.

  • Revenue in EUR (TTM)988.80k
  • Net income in EUR-4.13m
  • Incorporated2003
  • Employees28.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ATTANA AB485.82k-1.01m2.80m10.00--1.84--5.76-0.0367-0.03670.01680.04470.1945-0.48512.16552,453.00-40.62-37.18-52.55-46.66129.03175.97-208.89-254.690.3496-5.530.1539---32.896.615.80--8.21--
Truspine Technologies PLC0.00-557.26k3.16m1.00--0.8555-----0.004-0.0040.000.02050.00----0.00-13.14-21.97-16.58-26.49-----------32.310.0984------23.29--21.72--
Chordate Medical Holding AB (publ)97.92k-2.47m3.22m3.00--1.32--32.87-0.0906-0.09060.00360.05680.0289-0.37089.70371,183.30-72.99-91.98-86.88-122.85160.96209.52-2,522.81-3,295.753.43--0.00--799.630.6511-4.45------
Deltex Medical Group plc2.10m-1.51m3.25m37.00--0.8141--1.55-0.0012-0.00120.00150.00180.29740.84715.6148,000.00-21.47-14.66-29.13-21.8163.3471.84-72.18-32.931.13-2.980.3793---28.44-18.55-11.97--9.78--
CM International SA4.82m-664.49k3.41m38.00--1.91--0.7067-2.38-2.3817.266.370.81451.474.97432,667.70-11.236.06-17.8910.1743.2247.31-13.794.030.3705-10.570.00---8.5921.44-91.10-40.99-3.80--
Zortrax SA2.99m-20.26m3.56m57.00--0.132--1.19-0.7564-0.75640.11161.010.08872.0013.85---60.14---68.07--49.17---677.98--0.7924-172.030.0414---62.55---893.77------
Scandinavian ChemoTech AB361.69k-1.69m3.75m6.00--4.20--10.37-1.28-1.280.26410.4240.23270.32241.36685,500.00-108.95-87.29-108.95-118.5539.00252.05-468.27-2,122.77---15.730.00--496.6219.137.28------
Bioservo Technologies AB988.80k-4.13m4.25m28.00--1.25--4.30-0.1142-0.11420.0180.03970.25420.66454.12---106.14-48.11-137.96-55.308.5845.22-417.51-366.442.53-4,273.180.00--35.8215.59-45.65---29.68--
Airway Medix SA2.55k-874.70k4.25m1.00------1,665.91-0.0582-0.05820.0002-0.19360.0018--0.046111,000.00-60.79-29.65---46.85-18.18---34,272.73-7,957.75---27.13-----87.37-58.0391.36------
Surgical Innovations Group Plc14.19m-601.09k4.68m101.00--0.378115.990.33-0.0005-0.00050.01290.01120.80322.855.89118,950.50-3.40-8.19-4.18-9.9428.7032.51-4.24-13.311.23-4.450.1368--5.941.84-292.80--7.20--
Inhalation Sciences Sweden AB1.60m-287.30k4.74m8.00--4.43--2.96-0.21-0.211.320.80141.160.94137.492,273,250.00-20.80-27.93-35.65-43.8281.2571.13-17.96-48.022.68-2.920.071--43.5526.3360.87------
Nestmedic SA270.39k-1.48m4.79m8.00--4.18--17.70-0.2748-0.27480.04990.17960.08940.10332.14129,486.70-48.83-57.10-83.17-115.3067.8847.37-545.99-519.421.27-16.160.1887---17.0866.94-36.68---60.10--
iZafe Group AB440.05k-2.88m5.80m7.00--3.03--13.19-0.133-0.1330.02010.07910.1091.242.46714,857.10-71.38-52.17-82.09-69.40-10.99---655.02-487.500.6947--0.1174--149.93-24.79-36.76---41.66--
SciBase Holding AB (publ)2.12m-4.88m5.89m26.00--1.75--2.77-0.5255-0.52550.22370.24570.30040.78634.33894,592.60-69.07-68.63-90.03-87.7769.2861.28-229.94-300.201.78--0.00--29.9327.50-28.75--5.15--
ProstaLund AB1.77m-1.63m5.94m6.00--0.7949--3.36-0.2436-0.24360.26380.6340.39120.432511.14---36.07-29.14-40.73-35.0171.0575.26-92.21-68.941.90-126.960.0255--27.5410.36-53.27--20.35--
Data as of Jun 28 2024. Currency figures normalised to Bioservo Technologies AB's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.